SHIELD project

SHIELD is a partnership of 26 leading research centers, clinical sites, patient groups, and industry partners in 13 European countries. With a shared vision to tackle pancreatic cancer, SHIELD aims to develop a non-invasive blood test for early detection in individuals with high genetic risk, ultimately improving patient outcomes and survival in Europe and in the rest of the world. This project is funded by the European Union, under Grant Agreement no. 101214779. This work has received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).